NRG Therapeutics
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Gunnels Wood Rd, Stevenage, Hertfordshir...Website
www.nrgtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About NRG Therapeutics
NRG Therapeutics is a UK-based neuroscience-focused drug discovery company, established in 2018. They specialize in developing first-in-class, brain-penetrant, oral smallmolecule inhibitors targeting the mitochondrial permeability transition pore (mPTP) to restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinsons disease and Amyotrophic Lateral Sclerosis (ALS/MND)Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NRG Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NRG Therapeutics launches new products
NRG Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if NRG Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once NRG Therapeutics has new funding data
Click to see if NRG Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on NRG Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NRG Therapeutics
Check if NRG Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NRG Therapeutics
Compare insights from companies similar to NRG Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NRG Therapeutics
<$5M
1-10
Private
$88.6M
2018
N/A
Company Profile Activity
Activity Insights
NRG Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NRG Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NRG Therapeutics.
NRG Therapeutics financials insights
Gather financial insights about NRG Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$3.3M
Series A
$18.3M
2025
Series B
$67M
NRG Therapeutics Tech Stack
A closer look at the technologies used by NRG Therapeutics
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Funding
Funding
Executive Move
Board of Directors
Executive Move
Board of Directors
NRG Therapeutics News & Media
Michael J Fox Foundation adviser joins NRG Therapeutics - Business Weekly
NRG Therapeutics, a fast growing neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, has raided Cambridge's Mission Therapeutics to capture Paul Thompson as Chief Development Officer.NRG Therapeutics Announces Further Expansion with the Appointment of Paul Thompson as Chief Development Officer
STEVENAGE, United Kingdom, Dec. 01, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson, PhD, as Chief Development Officer (CDO).NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies
STEVENAGE, United Kingdom, Oct. 23, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
STEVENAGE, United Kingdom, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NRG Therapeutics
Sign Up For FreeTo access detailed company insights
NRG Therapeutics is a UK-based neuroscience-focused drug discovery company, established in 2018. They specialize in developing first-in-class, brain-penetrant, oral smallmolecule inhibitors targeting the mitochondrial permeability transition pore (mPTP) to restore mitochondrial function and slow or halt the progression of neurodegenerative diseases... Read More
